Today: 14 March 2026
Stellantis Stock Price Drops 5% as Bond Sale, China Talks Keep Investors Wary
14 March 2026
1 min read

Stellantis Stock Price Drops 5% as Bond Sale, China Talks Keep Investors Wary

NEW YORK, March 13, 2026, 19:25 EDT

Stellantis slid roughly 5.2% in New York on Friday, closing at $6.50. The Jeep and Peugeot parent extended its recent losses, with U.S. stocks broadly finishing down for both the session and the week. Reuters

Investors are watching closely, still weighing if Stellantis has truly moved past last month’s 22.2 billion euro impairment charge. The automaker lined up 5 billion euros in hybrid bonds this week—debt instruments with some characteristics of equity—and flagged plans to roll out a new long-term strategy on May 21. Stellantis.com

Pressed on whether adjusted operating income would bounce back into positive territory in North America and Europe this year, Chief Executive Antonio Filosa didn’t hesitate: “the answer is very easy, it is yes.” Filosa pointed out order books at the close of 2025 covered roughly three months’ worth of sales. He called last year’s outcome “the cost of overestimating the pace of the energy transition.” Stellantis, for its part, maintains that industrial free cash flow won’t see the black until 2027. Reuters

Investors are eyeing the prospect of outside support for Europe. According to Reuters, Bloomberg reported Thursday that Stellantis has been in discussions with Chinese automakers like Xiaomi and Xpeng, potentially seeking investment for its struggling European units, including Maserati. Stellantis pushed back on rumors of a breakup but confirmed it’s talking with other industry players. Reuters

Stellantis isn’t the only automaker retooling its EV strategy. Honda is looking at a $15.7 billion charge as it overhauls its electric vehicle operations, Reuters said Thursday. Ford and Volkswagen have also shelved or pushed back EV launches, faced with softer demand and tougher funding conditions. Reuters

Stellantis picked up a courtroom win after the bell on Friday. U.S. District Judge Valerie Caproni tossed out a would-be class action in Manhattan, where the company faced allegations of “channel stuffing”—that’s the practice of shoving extra vehicles onto dealerships to juice sales numbers in the short run. According to Caproni, shareholders failed to establish a convincing case for fraud or reckless behavior. Reuters

The court victory changes little about the big risk still looming. Back in February, S&P and Moody’s pushed Stellantis down to the lowest rung of investment grade—just a step above junk—blaming softer earnings and a dimmer cash-flow outlook. That downgrade means Stellantis can’t afford to slip much further. Reuters

As of March 12, Reuters stock data put shares listed in Milan at 5.97 euros, marking a drop of almost 47% over the past year. Investors aren’t biting yet—the price suggests they’re holding out for real signs of a turnaround before committing more. Reuters

Stock Market Today

  • CSL Commits A$1.5 Billion to Kankakee Site Expansion Despite Share Price Pressure
    March 13, 2026, 9:12 PM EDT. CSL (ASX:CSL) has pledged A$1.5 billion to expand its plasma therapy production facility in Kankakee, Illinois, aiming to boost output and create hundreds of U.S. jobs. Despite this, CSL's shares have dropped 13.71% in 30 days and lost 42.19% in total shareholder return over one year, reflecting investor caution. Analyst valuations suggest shares trade at a significant discount, with a fair value estimated at A$263.33 versus the recent close of A$141.03. Key factors influencing value include earnings growth, margin recovery at CSL Behring, and industry competition. Investors face a pivotal decision: seize a potential buying opportunity or account for pricing-in of future growth amid risks such as margin setbacks and U.S. trade tariffs. CSL's expansion highlights ongoing shifts in healthcare investment priorities.
Oracle Stock Price Slides as $2.1 Billion Restructuring Bill Tests ORCL’s AI Rally
Previous Story

Oracle Stock Price Slides as $2.1 Billion Restructuring Bill Tests ORCL’s AI Rally

Warner Bros. Discovery Stock Price Falls as California Review Clouds Paramount’s $31 Deal
Next Story

Warner Bros. Discovery Stock Price Falls as California Review Clouds Paramount’s $31 Deal

Go toTop